Matthew Jones
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Year:
2026
Year:
2026
Charting the spatiotemporal dynamics of cell fate determination in development and disease is a long-standing objective in biology. Here, we present the design, development, and extensive validation of PEtracer, a prime editing (PE)–based, evolving lineage tracing technology compatible with both single-cell sequencing and multimodal imaging methodologies, created to jointly profile cell state and lineage in dissociated cells or while preserving cellular context in tissues with high spatial resolution. Using PEtracer coupled with MERFISH spatial transcriptomic profiling in a syngeneic mouse model of tumor metastasis, we reconstructed the growth of individually seeded tumors in vivo and uncovered distinct modules of cell-intrinsic and -extrinsic factors that coordinate tumor growth. More generally, PEtracer enables systematic characterization of cell state and lineage relationships in intact tissues over biologically relevant temporal and spatial scales.
Year:
2025
Oncogene amplification on extrachromosomal DNA (ecDNA) is a pervasive driver event in cancer, yet our understanding of how ecDNA forms is limited. In this study, we couple a CRISPR-based method for ecDNA induction with extensive characterization of newly formed ecDNAs to examine their biogenesis. We find that DNA circularization is efficient, irrespective of 3D genome context, with the formation of 800 kb, 1 Mb, and 1.8 Mb ecDNAs reaching or exceeding 15%. We show nonhomologous end joining and microhomology-mediated end joining both contribute to ecDNA formation, whereas inhibition of DNA-PK catalytic subunit and ATM have opposing impacts on ecDNA formation. ecDNA and the corresponding chromosomal excision scar can form at significantly different rates and respond differently to DNA-PK catalytic subunit and ATM inhibition. Taken together, our results support a model of ecDNA formation in which double-strand break ends dissociate from their legitimate ligation partners prior to joining of illegitimate ends to form the ecDNA and excision scar. Significance: Our study harnesses a CRISPR-based method to examine ecDNA biogenesis, uncovering efficient circularization between double-strand breaks. ecDNAs and their corresponding chromosomal scars can form via nonhomologous end joining or microhomology-mediated end joining, but the ecDNA and scar formation processes are distinct. Based on our findings, we establish a mechanistic model of excisional ecDNA formation.
Year:
2025
Foundation models have transformed natural language processing and computer vision, yet their potential in single-cell biology—particularly for complex diseases such as cancer— remains underexplored. We present Tahoe-x1 (Tx1), a family of perturbation-trained single-cell foundation models with up to 3 billion parameters. Tx1 is pretrained on large-scale single-cell transcriptomic datasets, including the Tahoe-100M perturbation compendium, and fine-tuned for cancer-relevant tasks. Through architectural optimizations, data loader refinements, and efficient training strategies, Tx1 achieves 3–30× higher compute efficiency than prior implementations of cell-state models. Tx1 jointly learns representations of genes, cells, and compounds using a masked-expression generative objective that incorporates a drug token, enabling flexible adaptation to diverse downstream applications. We evaluate Tx1 across four key disease-relevant benchmarks: (1) prediction of overall and context-specific gene essentiality, (2) identification of genes contributing to the hallmarks of cancer, (3) cell-type classification, and (4) prediction of perturbation responses in held-out cellular contexts. Tx1 achieves state-of-the-art performance across all tasks. We release pretrained checkpoints, training code, and evaluation workflows to accelerate the development of perturbation-trained single-cell foundation models for applications in precision oncology and beyond.
Year:
2025
Workflow of the study analysis. A, A total of 94 IDH wt GBMs were analyzed (35 from the PCAWG cohort and 59 from the GB-UK cohort). B, The core region of all patient tumors was analyzed using WGS, and GB-UK patient tumors were further subjected to multiregion DNA FISH and nascent RNAscope analysis to characterize spatial patterns of oncogenic ecDNAs. C, The ecDNA genetic landscape and fine structure were analyzed using WGS information, and mathematical modeling of single-cell copy number was employed to reconstruct evolutionary histories in GB-UK patient tumors. ( B, created using BioRender assets. https://BioRender.com/kgae4q5 ; https://BioRender.com/7f2pume )
Year:
2025
Oncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly understood. In this study, we integrate computational modeling with samples from 94 treatment-naive human glioblastomas (GBM) to investigate the spatiotemporal evolution of ecDNA. We observe oncogene-specific patterns of ecDNA spatial heterogeneity, emerging from random ecDNA segregation and differing fitness advantages. Unlike PDGFRA -ecDNAs, EGFR -ecDNAs often accumulate prior to clonal expansions, conferring strong fitness advantages and reaching high abundances. In corroboration, we observe pretumor ecDNA accumulation in vivo in genetically engineered mouse neural stem cells. Variant and wild-type EGFR -ecDNAs often coexist in GBM. Those variant EGFR -ecDNAs, most commonly EGFRvIII -ecDNA, always derive from preexisting wild-type EGFR -ecDNAs, occur early, and reach high abundance. Our results suggest that the ecDNA oncogenic makeup determines unique evolutionary trajectories. New concepts such as ecDNA clonality and heteroplasmy require a refined evolutionary interpretation of genomic data in a large subset of GBMs. Significance: We study spatial patterns of ecDNA-amplified oncogenes and their evolutionary properties in human GBM, revealing an ecDNA landscape and ecDNA oncogene–specific evolutionary histories. ecDNA accumulation can precede clonal expansion, facilitating the emergence of EGFR oncogenic variants, reframing our interpretation of genomic data in a large subset of GBMs. See related commentary by Korsah et al., p. 1979
Year:
2025
Simulating multi-ecDNA dynamics in vivo. A, DNA FISH and nascent RNAscope images from the tumor of patient A5, showing the coexistence of both EGFR -ecDNA and PDGFRA -ecDNA. B, Circular structures of three distinct oncogenic ecDNAs detected in the tumor of patient A5. C, GBMs in the GB-UK and PCAWG cohorts containing more than one oncogenic species and their respective copy numbers. D, In a multiple-ecDNA application of SPECIES, the clone-initiating cell begins with k 1 and k 2 copies of ecDNA 1 and ecDNA 2, respectively. E, Representation of the impacts of ecDNA cosegregation and coselection on the number of inherited ecDNA copies during cell division. Cosegregation drives correlated inheritance of both ecDNA types, whereas coselection favors tumor cells carrying at least one copy of each type. F, Application of SPECIES to simulate two separate ecDNA species. Simulated tumors were initialized with a single cell, carrying k 1 and k 2 copies of each ecDNA species. Representative model images show examples of low and high cosegregation and coselection. G and H, Parameter inference summary for the tumor of patient A5, for which we measured both the EGFR -ecDNA and PDGFRA -ecDNA copy-number distributions using DNA FISH, using multiple-ecDNA SPECIES. Parameters s p and s m represent selection coefficients for tumor cells with 1 (pure) or 2 (mixed) ecDNA species, respectively. I, Comparison of inferred k and k 1 values for all patient tumors confirmed by WGS to harbor two or more ecDNA species. J, The presence of ecDNA amplifications may be used to aid stratification, given that oncogenes on ecDNA have an inherent resistance mechanism through the ability of ecDNA to dynamically adjust copy number in response to targeted agents. Earlier monitoring and intervention are recommended for those patient tumors with ecDNA that will receive targeted therapies.
Year:
2025
Selection dynamics of EGFR SVs on ecDNA. A, A subclonal EGFRvIII variant on ecDNA in the tumor of patient A23. B, Variant heteroplasmy in the core region of all samples across the GB-UK and PCAWG cohorts, which contained EGFR variant–bearing ecDNA. C, Effects of (i) pre- and (ii) postclonal expansion mutation of EGFR -ecDNA on its resulting spatial pattern in the expanded tumor. D, SPECIES was applied to simulate the emergence of an advantageous EGFRvIII mutation on ecDNA, either prior to or after the onset of clonal expansion of the tumor. The example shown is for a pre-expansion mutation, with parameters ( k w t = 20 , k v a r = 1 , V v a r = 0 ). The SD of ecDNA heteroplasmy is shown by the shaded region in the lower plot. E, Model predictions for resulting variant heteroplasmy in a tumor for a range of wild type- and variant-bearing ecDNA copy numbers in the clone-initiating tumor cell (for pre-expansion EGFR mutation) and mutation times (for post-expansion EGFR mutation). The red-shaded region denotes parameter combinations inconsistent with observed patient core heteroplasmy values. Mean ± variance is derived from 1,000 simulated tumors. F, SPECIES model predictions for the probability of observing EGFRvIII ecDNA across tumor core and margin, for a pair of core and random margin regions. Mean values are derived from 1,000 simulated tumors. G, (Top) IHC slide for the tumor of patient A20, showing the presence of EGFRvIII in the tumor core and infiltrating margin (blue = hematoxylin; brown = EGFRvIII ). (Bottom) Summary of EGFRvIII in core and margins of GB-UK cohort samples, determined by IHC. H, Variant allele frequencies of point mutations within EGFR in PCAWG samples harboring EGFR -ecDNA. Red lines represent the frequency expected for a mutation carried by all ecDNAs within a sample. I, Distributions of EGFR wt-ecDNA abundance in the cell that acquires the first mutation, for a range of ecDNA mutation rates. Patient tumor values are derived from their respective inferred k values, assuming that the arrival of a mutation on ecDNA initiates clonal expansion, implying that the number of EGFR wt-ecDNA in the mutating cell is thus equal to k − 1 (with the remaining one ecDNA carrying the mutated allele). J, Timeline of EGFR -ecDNA tumorigenesis. ( i ) Initial EGFR wt-ecDNA is generated and accumulates in precancerous cells, conferring a moderately positive selective advantage. In time, the EGFRvIII mutation occurs on one of the accumulated EGFR wt-ecDNAs, conferring a strong positive advantage. ( ii ) Reconstructed ecDNA structures from the tumor of GB-UK patient A5 confirm that EGFR wt and EGFRvIII ecDNAs share common breakpoints, indicating that EGFRvIII arose from the mutation of an existing EGFR wt-ecDNA. (iii) EGFRvIII -ecDNA further promotes clonal expansion, driving tumor growth.
Year:
2025
SPECIES spatial modeling of ecDNA evolution. A and B, DNA FISH staining of two representative GBM samples from the GB-UK cohort, revealing ( A ) EGFR - and ( B ) PDGFRA -ecDNA. EGFR -ecDNA seem to congregate into “hubs” (white arrows). Single-cell ecDNA copy-number distributions are derived from DNA FISH images using unbiased image analysis. C, (i) SPECIES is initiated with a single tumor cell containing k copies of ecDNA. (ii) Model of ecDNA selection. Cells carrying one or more copies of ecDNA divide at a rate s faster than cells lacking ecDNA. (iii) Cells push neighbors within a radius q on the lattice to make space required for cell division. D, Spatial computational model of ecDNA-driven tumors. ABC was used to infer optimal model parameters for the initial number of ecDNA, k ; ecDNA-conferred selection, s ; and cell pushing strength, q , for a given set of patient tumor measurements. E and F, Example output of the ABC model fitting algorithm using ( E ) 2 and ( F ) 3 spatial regions. (Left to right) Inferred k , s , and q and model best-fit distributions for each tumor region. The sum of the Wasserstein distance between patient and simulated distributions for each tumor region, representing closeness of fit, is denoted by σ. G, Comparison of inferred k , s , and q when analyzing 2 (core and margin) vs. 3 (core, margin, and leading edge) spatial regions. H, Summary of inferred model parameters for all sampled human GBM tumors. The highlighted color represents ecDNA-amplified oncogenes ( EGFR , PDGFRA , or CDK4 ) in each tumor. I, Inferred model parameters for all patient tumors (excluding the tumor of patient A5, which contained separate EGFR- and PDGFRA -ecDNA species), stratified by ecDNA-amplified oncogene ( EGFR or PDGFRA ). ( D, created using BioRender assets. https://BioRender.com/7f2pume )
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (23)
Xiaowei Zhuang
Harvard University
Can Ergen
Group Leader
Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit
Vineet Bafna
Professor
University of California, San Diego
Charles Swanton
Chief Clinician
-
Andrea Ventura
Member
Memorial Sloan Kettering Cancer Center
Benjamin Werner
Reader in Somatic Evolution
Barts Cancer Institute
Luke Koblan
Whitehead Institute for Biomedical Research
Jonathan Weissman
Whitehead Institute for Biomedical Research
Mariam Jamal-Hanjani
Group Leader and Thoracic Oncologist
University College London
Nir Yosef
Weizmann Institute of Science
Thomas Santarius
University of Cambridge
Howard Y. Chang
Stanford University School of Medicine
Edridge D'Souza
Columbia University
Clare Weeden
The Francis Crick Institute
Delphine Boche
Professor of Neuroimmunopathology
University of Southampton
Weini Huang
Senior Lecturer
Queen Mary University of London
Brooke E. Howitt
Stanford University School of Medicine
Calvin Kuo
Professor
Stanford University
Hani Goodarzi
Associate Professor
University of California, San Francisco
Paul S. Mischel
Stanford University School of Medicine
Natasha Weiser
Assistant Professor
Yale University
William Allen
Assistant Professor
Stanford University
Mary Green
Deputy Head of Experimental Histopathology
The Francis Crick Institute
Make your next move.
Prepare your application
Review drafts before you send them.